Glioblastoma is a formidable brain malignancy known for its fast growth and insensitivity to standard treatments. Investigations are constantly underway to identify new management strategies, and recently, a novel biomarker named LCA168 has emerged as a potential target for GBM treatment. LCA168 is a protein that is overexpressed in GBM cells comp